other material
confidence high
sentiment positive
materiality 0.60
Catalyst reaffirms FY2023 revenue $375M-$385M; non-GAAP net income $195M-$205M
CATALYST PHARMACEUTICALS, INC.
- Reaffirms full-year 2023 total revenue guidance of $375M to $385M, 75-80% YoY increase.
- FIRDAPSE net product revenue guided $245M-$255M, up 17% vs. 2022.
- FYCOMPA net product revenue forecast at ~$130M for 11 months after Jan. 24 acquisition.
- Non-GAAP net income forecast of $195M to $205M for full-year 2023.